Literature DB >> 18652829

Involvement of non-conserved residues important for PGE2 binding to the constrained EP3 eLP2 using NMR and site-directed mutagenesis.

Annirudha Chillar1, Jiaxin Wu, Shui-Ping So, Ke-He Ruan.   

Abstract

A peptide constrained to a conformation of second extracellular loop of human prostaglandin-E(2) (PGE(2)) receptor subtype3 (hEP3) was synthesized. The contacts between the peptide residues at S211 and R214, and PGE(2) were first identified by NMR spectroscopy. The results were used as a guide for site-directed mutagenesis of the hEP3 protein. The S211L and R214L mutants expressed in HEK293 cells lost binding to [(3)H]PGE(2). This study found that the non-conserved S211 and R214 of the hEP3 are involved in PGE(2) recognition, and implied that the corresponding residues in other subtype receptors could be important to distinguish the different configurations of PGE(2) ligand recognition sites.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18652829      PMCID: PMC2677024          DOI: 10.1016/j.febslet.2008.07.018

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  21 in total

1.  Mutagenic analysis of platelet thromboxane receptor cysteines. Roles in ligand binding and receptor-effector coupling.

Authors:  D D D'Angelo; J J Eubank; M G Davis; G W Dorn
Journal:  J Biol Chem       Date:  1996-03-15       Impact factor: 5.157

2.  Point mutation in the seventh hydrophobic domain of the human thromboxane A2 receptor allows discrimination between agonist and antagonist binding sites.

Authors:  C D Funk; L Furci; N Moran; G A Fitzgerald
Journal:  Mol Pharmacol       Date:  1993-11       Impact factor: 4.436

3.  The short-neurotoxin-binding regions on the alpha-chain of human and Torpedo californica acetylcholine receptors.

Authors:  K H Ruan; B G Stiles; M Z Atassi
Journal:  Biochem J       Date:  1991-03-15       Impact factor: 3.857

4.  The second extracellular loop of the prostaglandin EP3 receptor is an essential determinant of ligand selectivity.

Authors:  L Audoly; R M Breyer
Journal:  J Biol Chem       Date:  1997-05-23       Impact factor: 5.157

5.  Impaired adrenocorticotropic hormone response to bacterial endotoxin in mice deficient in prostaglandin E receptor EP1 and EP3 subtypes.

Authors:  Yoko Matsuoka; Tomoyuki Furuyashiki; Haruhiko Bito; Fumitaka Ushikubi; Yasuhiro Tanaka; Takuya Kobayashi; Seiji Muro; Noriko Satoh; Tetsuro Kayahara; Mikito Higashi; Akira Mizoguchi; Hitoshi Shichi; Yoshihiro Fukuda; Kazuwa Nakao; Shuh Narumiya
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

6.  Third isoform of the prostaglandin-E-receptor EP3 subtype with different C-terminal tail coupling to both stimulation and inhibition of adenylate cyclase.

Authors:  A Irie; Y Sugimoto; T Namba; A Harazono; A Honda; A Watabe; M Negishi; S Narumiya; A Ichikawa
Journal:  Eur J Biochem       Date:  1993-10-01

7.  Site-directed mutagenesis of cysteinyl and serine residues of human thromboxane A2 receptor in insect cells.

Authors:  N Chiang; W M Kan; H H Tai
Journal:  Arch Biochem Biophys       Date:  1996-10-01       Impact factor: 4.013

8.  Two isoforms of the EP3 receptor with different carboxyl-terminal domains. Identical ligand binding properties and different coupling properties with Gi proteins.

Authors:  Y Sugimoto; M Negishi; Y Hayashi; T Namba; A Honda; A Watabe; M Hirata; S Narumiya; A Ichikawa
Journal:  J Biol Chem       Date:  1993-02-05       Impact factor: 5.157

9.  Synthesis of the antibacterial peptide cecropin A (1-33).

Authors:  R B Merrifield; L D Vizioli; H G Boman
Journal:  Biochemistry       Date:  1982-09-28       Impact factor: 3.162

10.  The prostaglandin E2 analogue sulprostone antagonizes vasopressin-induced antidiuresis through activation of Rho.

Authors:  Grazia Tamma; Burkhard Wiesner; Jens Furkert; Daniel Hahm; Alexander Oksche; Michael Schaefer; Giovanna Valenti; Walter Rosenthal; Enno Klussmann
Journal:  J Cell Sci       Date:  2003-06-26       Impact factor: 5.285

View more
  4 in total

Review 1.  [Novel achievements in development and application of GPCR-peptides].

Authors:  A O Shpakov; K V Derkach
Journal:  Zh Evol Biokhim Fiziol       Date:  2015 Jan-Feb

2.  Latest progress in the development of cyclooxygenase-2 pathway inhibitors targeting microsomal prostaglandin E2 synthase-1.

Authors:  Krista LaBorde; Renzhong Lu; Ke-He Ruan
Journal:  Future Med Chem       Date:  2022-01-05       Impact factor: 3.808

Review 3.  Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer.

Authors:  M T M van Jaarsveld; J M Houthuijzen; E E Voest
Journal:  Oncogene       Date:  2015-12-07       Impact factor: 9.867

4.  Cellular production of n-3 PUFAs and reduction of n-6-to-n-3 ratios in the pancreatic beta-cells and islets enhance insulin secretion and confer protection against cytokine-induced cell death.

Authors:  Dong Wei; Jie Li; Miaoda Shen; Wei Jia; Nuoqi Chen; Tao Chen; Dongming Su; Haoming Tian; Shusen Zheng; Yifan Dai; Allan Zhao
Journal:  Diabetes       Date:  2009-11-23       Impact factor: 9.461

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.